Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal Article (Journal Article)

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

Full Text

Duke Authors

Cited Authors

  • Deininger, MW; Shah, NP; Altman, JK; Berman, E; Bhatia, R; Bhatnagar, B; DeAngelo, DJ; Gotlib, J; Hobbs, G; Maness, L; Mead, M; Metheny, L; Mohan, S; Moore, JO; Naqvi, K; Oehler, V; Pallera, AM; Patnaik, M; Pratz, K; Pusic, I; Rose, MG; Smith, BD; Snyder, DS; Sweet, KL; Talpaz, M; Thompson, J; Yang, DT; Gregory, KM; Sundar, H

Published Date

  • October 1, 2020

Published In

Volume / Issue

  • 18 / 10

Start / End Page

  • 1385 - 1415

PubMed ID

  • 33022644

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2020.0047


  • eng

Conference Location

  • United States